Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

The EMPOWER-Lung 1 RCT found that cemiplimab monotherapy significantly improved survival vs chemotherapy (n=710; median overall survival not yet reached vs 14.2 months; HR, 0.57; p=0.0002: progression-free survival 8.2 vs 5.7 months; HR 0.54; p<0.0001).

The Lancet